The Department of Health - Abu Dhabi (DoH), the regulator of the healthcare sector in the Emirate, in partnership with PureHealth, Khalifa University of technology (KU), Illumina, M42, Institute for Healthier Living Abu Dhabi (IHLAD) and New York University Abu Dhabi (NYUAD), has signed a landmark Memorandum of Understanding (MoU) to establish a collaborative framework that will shape the future of healthcare through precision medicine and advanced therapies.
This multi-stakeholder collaboration will focus on establishing genomic infrastructure and population health programmes tailored to Emirati and regional populations. It will also focus on launching research and development initiatives in advanced therapeutics such as gene therapy and cell-based treatments and support the integration of precision medicine into clinical practice, through pharmacogenomics and genome testing.
Additionally, the partnership will build artificial intelligence (AI) and digital platforms for genomic data analysis and personalised patient care, as well as education and training pathways to develop local expertise in genomic and precision medicine.
Four core themes will guide discussions and initiatives: Longevity and Precision Health; Health System Resilience & Sustainability; Digital Health & AI; and Investment in Life Sciences.
